We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Probiotix Health plc (PBX) ORD GBP0.05

Sell:4.00p Buy:6.00p Change: No change
Prices delayed by at least 15 minutes | Switch to live prices |
Change: No change
Prices delayed by at least 15 minutes | Switch to live prices |
Change: No change
Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

ProBiotix Health plc is a United Kingdom-based life sciences company. The Company is engaged in the development of probiotics to tackle cardiovascular disease and other lifestyle conditions. Its principal product, Lactobacillus plantarum ECGC13110402 (LP-LDL), can reduce key cardiovascular risk biomarkers, such as total cholesterol, LDL (bad) cholesterol and blood pressure, by 36.7 per cent, 13.9 per cent and 5.1 per cent respectively. The Company's CholBiome products contains LP-LDL. Its products are commercialized in 60 countries. The CholBiome portfolio comprised four products, which can either be sold under the CholBiome brand or customers’ private labels: CholBiome, CholBiomeX3, CholBiomeBP and CholBiomeVH. CholBiome contains LPLDL to focus on healthy cholesterol maintenance and deliver tangible health benefits. CholBiomeX3 consists of LPLDL, Monacolin K from red yeast rice, and Vitamin B3 (niacin) to reduce cholesterol and aid overall cardiovascular health.

Contact details

Innovation Centre
Innovation Way, Heslington
YO10 5DG
United Kingdom
+ (0)

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Market cap:
£6.08 million
Shares in issue:
121.67 million
Sterling pence

Key personnel

  • Steen Andersen
    Chief Executive Officer, Director
  • Mark Collingbourne
    Chief Financial Officer, Company Secretary

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.